StockData
Genmab A/S logo

Genmab A/S

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.97−0.99 (-1.91%)

Close on Nov 18, 2026

Genmab A/S Total Revenue by Collaboration Partner & Product Channel

Total Revenue by Collaboration Partner & Product Channel ($M)

Genmab A/S Total Revenue by Collaboration Partner & Product Channel: $1,038M in Q3 2026, up 13.1% from a year earlier. That is the highest of the 11 quarters on record here.

Latest, Q3 2026
1,038
Period ended Sep 30, 2026
Change on a year earlier
+13.1%
918 in Q3 2025
History
11 quarters
Since Q1 2024
Sources
7
Documents cited below

Where the Q3 2026 figure comes from

“|| Total* | $ | 1,038 | $ | 918 | $ | 2,828 | $ | 2,382”

Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗

Consolidated revenue disaggregated by collaboration counterparty plus direct net product sales (Note 2.1 / Note 3).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up total Revenue by Collaboration Partner & Product Channel

Cite this data

StockData. (2026). Genmab A/S Total Revenue by Collaboration Partner & Product Channel ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/partner-total

See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.

See a number that looks wrong?